Furthermore, VIR-2482 could have the potential to overcome the limitations of current flu vaccines and result in higher levels of protection, given it does not rely on an individual to create ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory submissions.

Arizona State Retirement System’s holdings in Vir Biotechnology were worth $189,000 ... The disclosure for this sale can be found here. Over the last three months, insiders sold 30,859 shares ...